Introduction
============

Individuals with myasthenia gravis (MG) face difficulty in maintaining daily activities and are required to cope with a chronic condition of weakness and fatigability of variable and fluctuating severity.[@b1] [@b2] Chronic and disabling disease conditions often lead to psychiatric consequences, such as anxiety and depressive disorders.[@b1] [@b2] The constant need for medications may decrease quality of life and cause psychological stress.[@b1] [@b2] Depressive symptoms have long been suggested to be common in patients with MG and extent to which and how depressive symptoms are involved in MG has been a matter of some discussion.[@b1; @b2; @b3; @b4] However, disease-specific psychopathological backgrounds remain undefined and results from psychological testing have been inconsistent.[@b1; @b2; @b3] The frequency of depressive symptoms in patients with MG has also been inconsistently reported using different measures.[@b1; @b2; @b3] Although an intricate relationship to MG appears to exist, previous studies were small scale and did not clearly show causal backgrounds of depressive symptoms in MG.[@b1] [@b2]

The present study evaluated self-reported symptoms of depression in a sample of 287 patients with MG using a standardised measure, the Beck Depression Inventory--Second Edition (BDI-II),[@b5] [@b6] and systematically and statistically examined associations with detailed clinical parameters of MG. The purpose of this study was to clarify clinical factors associated with depressive state in patients with MG.

Patients and methods
====================

Patients
--------

This cross-sectional study was conducted at six neurological centres located in Eastern Japan (three in Tohoku district and three in Tokyo area, East Japan MG study group). We evaluated 287 consecutive non-demented patients with MG seen at Sendai Medical Center, Hanamaki General Hospital, Tohoku University Hospital, Keio University Hospital, Tokyo Medical University Hospital and Tokyo Women\'s Medical University Hospital from May until August 2010. To avoid a potential bias, we enrolled consecutive patients during short duration (3 months). Patients with any missing clinical data were excluded. All patients provided written informed consent and were subjected to analysis. Clinical background data for the 287 patients with MG are shown in [table 1](#tbl1){ref-type="table"}.

###### 

Backgrounds of patients and correlations of clinical factors with BDI-II score

  Clinical factors                                                   Patient backgrounds (287 in total)      Correlation (95% CI)     p Value
  ------------------------------------------------------------------ --------------------------------------- ------------------------ ----------------------------------------------
  Age (years)                                                        57.5±17.1                               −0.05 (−0.16 to 0.07)    0.200
  Female[\*](#table-fn1){ref-type="table-fn"}                        n=193                                   0.19 (0.07 to 0.30)      0.001[†](#table-fn2){ref-type="table-fn"}
  Time since onset (years)                                           8.9±8.3                                 −0.08 (−0.19 to 0.04)    0.10
  Age at onset (years)                                               48.0±18.6                               −0.01 (−0.13 to 0.10)    0.41
  Thymectomy[\*](#table-fn1){ref-type="table-fn"}                    n=141                                   0.02 (−0.10 to 0.13)     0.39
  Thymoma[\*](#table-fn1){ref-type="table-fn"}                       n=63                                    0.06 (−0.05 to 0.18)     0.15
  QMG                                                                7.0±5.1                                 0.33 (0.22 to 0.43)      \<0.0001[†](#table-fn2){ref-type="table-fn"}
  Ocular QMG                                                         1.7±1.8                                 0.29 (0.17 to 0.39)      \<0.0001[†](#table-fn2){ref-type="table-fn"}
  Bulbar QMG                                                         0.3±0.8                                 0.14 (0.02 to 0.25)      0.01[†](#table-fn2){ref-type="table-fn"}
  MG composite                                                       5.8±5.7                                 0.40 (0.30 to 0.50)      \<0.0001[†](#table-fn2){ref-type="table-fn"}
  MG-ADL                                                             3.4±3.1                                 0.39 (0.29 to 0.49)      \<0.0001[†](#table-fn2){ref-type="table-fn"}
  MGFA classification (worst)[\*](#table-fn1){ref-type="table-fn"}   I/II/III/IV/V: 68/125/60/12/22          0.17 (0.05 to 0.28)      0.002[†](#table-fn2){ref-type="table-fn"}
  Current dose of PSL (mg/day)                                       4.6±5.9                                 0.33 (0.22 to 0.43)      \<0.0001[†](#table-fn2){ref-type="table-fn"}
  Maximum dose of PSL (mg/day)                                       20.5±20.7                               0.02 (−0.09 to 0.14)     0.34
  Calcineurin inhibitors[\*](#table-fn1){ref-type="table-fn"}        n=115                                   0.07 (−0.04 to 0.19)     0.10
  Crisis[\*](#table-fn1){ref-type="table-fn"}                        n=22                                    0.02 (−0.10 to 0.14)     0.38
  AChR-Ab positivity[\*](#table-fn1){ref-type="table-fn"}            n=232                                   −0.14 (−0.25 to −0.02)   0.01[†](#table-fn2){ref-type="table-fn"}
  Kv 1.4-Ab positivity[\*](#table-fn1){ref-type="table-fn"}          n=37                                    0.05 (−0.08 to 0.18)     0.22
  Titin-Ab positivity[\*](#table-fn1){ref-type="table-fn"}           n=53                                    0.09 (−0.07 to 0.26)     0.10
  MuSK-Ab positivity[\*](#table-fn1){ref-type="table-fn"}            n=2 (of 55 AChR Ab-negative patients)   Not determined           Not determined
  CSR[\*](#table-fn1){ref-type="table-fn"}                           n=21                                    −0.10 (−0.22 to 0.01)    0.04[†](#table-fn2){ref-type="table-fn"}
  PR[\*](#table-fn1){ref-type="table-fn"}                            n=22                                    −0.09 (−0.20 to 0.03)    0.08
  MM[\*](#table-fn1){ref-type="table-fn"}                            n=95                                    −0.17 (−0.28 to −0.06)   0.002[†](#table-fn2){ref-type="table-fn"}
  I[\*](#table-fn1){ref-type="table-fn"}                             n=91                                    0.12 (0.01 to 0.23)      0.02[†](#table-fn2){ref-type="table-fn"}
  U[\*](#table-fn1){ref-type="table-fn"}                             n=54                                    0.13 (0.02 to 0.24)      0.01[†](#table-fn2){ref-type="table-fn"}
  W[\*](#table-fn1){ref-type="table-fn"}                             n=4                                     0.03 (−0.08 to 0.15)     0.28

Pearson\'s correlation or Spearman\'s rank correlation.

Variables entered into multivariate regression analysis (see the Results section in the text).

AChR-Ab, antibodies against acetylcholine receptor; BDI-II, Beck Depression Inventory--Second Edition; CSR, complete stable remission; I, improved; Kv1.4, voltage-gated potassium channel 1.4; MG, myasthenia gravis; MG-ADL, MG activities of daily living scale; MG composite, MG composite scale; MGFA, Myasthenia Gravis Foundation of America; MM, minimal manifestations; MuSK, muscle-specific tyrosine kinase; PR, pharmacologic remission; PSL, prednisolone; QMG, MGFA quantitative MG score; U, unchanged; W, worse.

The diagnosis of MG was based on clinical findings (fluctuating symptoms with easy fatigability and recovery after rest) with reductions in symptoms after intravenous administration of anticholinesterase, decremental muscle response to a train of low-frequency repetitive nerve stimuli or the presence of antibodies against the acetylcholine receptor of skeletal muscle (AChR-Ab) or against muscle-specific tyrosine kinase (MuSK-Ab). Single-fibre electromyography was not systematically examined. AChR-Ab-negative cases comprised 55 of 287 patients. Two of the 55 AChR-Ab-negative patients were MuSK-Ab-positive.

Clinical parameters
-------------------

All patients completed the BDI-II, a 21-item self-administered questionnaire designed to detect symptoms of depression and assess the severity of depression.[@b5] [@b6] BDI-II has been shown to represent a reliable and valid measure of depression.[@b5] [@b6] According to standardised scoring guidelines in the original English version, scores were categorised as indicative of moderate (20--28 points) or severe depression (≥29 points).[@b5; @b6; @b7] The Japanese version of the BDI-II has also been validated, and the mean score of the Japanese standard population reported as 8.7±6.4,[@b8] somewhat lower than that of the original English version.

Clinical factors shown in [table 1](#tbl1){ref-type="table"} were evaluated for each patient and entered into analysis. Clinical severity at study entry was determined by patients and participating neurologists according to the MG Foundation of America (MGFA) quantitative MG score (QMG),[@b9] MG activities of daily living scale (MG-ADL)[@b10] and MG composite scale (MG composite).[@b11] Clinical state at study entry following treatment was categorised according to MGFA postintervention status.[@b9] The worst condition for each patient was classified according to the MGFA classification.[@b9] Prednisone and prednisolone (PSL) are the standard agents for oral corticosteroid therapy in MG, and PSL is generally used in Japan. Dose of oral PSL was evaluated for both the current and maximum dosage.

Serum AChR-Ab titres were estimated by radioimmunoassay using ^125^I-α-bungarotoxin, with levels ≥0.5 nM regarded as positive. MG-specific autoantibodies to voltage-gated potassium channel (Kv1.4-Ab) were detected by immunoprecipitation assay using ^35^S-labelled cellular extracts as the antigen source, as described elsewhere.[@b12] Autoantibodies to titin (titin-Ab) was detected using a commercially available ELISA (DLD Diagnostika, Hamburg, Germany). MuSK-Ab was measured using a commercially available radioimmunoprecipitation assay (RSR, Cardiff, UK).

Statistics
----------

Correlations between clinical factors and BDI-II score were evaluated using Pearson\'s correlation for continuous variables or Spearman\'s rank correlation for categorical variables converted to numerical variables. Factors found to have a p value of \<0.05 in univariate analysis were entered into multivariate linear regression analysis.

Differences between the two groups were evaluated using the Mann--Whitney U test for continuous variables and the χ^2^ test for categorical variables. Clinical factors associated with depressive state indicated by BDI-II \>21.5 were examined by logistic regression analysis. Clinical factors found to have a p value of \<0.05 in univariate analysis were entered into multivariate logistic regression analysis to determine background factors independently associated with depressive state.

p Values of \<0.05 were considered statistically significant. All continuous data are expressed as mean ± SD. Statistical analyses were performed using UNISTAT V.5.6 statistical software (Unistat, London, UK).

Results
=======

Correlations of clinical factors to BDI-II score
------------------------------------------------

Positive correlations to BDI-II score were found for female sex, total QMG, ocular QMG, bulbar QMG, MG composite, MG-ADL, MGFA classification at the worst condition, current dose of PSL, and Improved (I) and Unchanged (U) MGFA postintervention status ([table 1](#tbl1){ref-type="table"}). Negative correlations were seen for AChR-Ab-positivity, and Complete Stable Remission and Minimal Manifestations MGFA postintervention status ([table 1](#tbl1){ref-type="table"}). These clinical factors were entered into multivariate linear regression analysis, which revealed severity (MG composite, p=0.008; MG-ADL, p=0.003) and current dose of PSL (p=0.0002) as factors with independent positive effects on BDI-II total score. However, as mean BDI-II score for the 287 patients with MG was 11.0±8.1 and did not differ substantially from and overlapped with that reported as the Japanese standard (8.7±6.4),[@b8] determining background factors for depressive state in MG using a linear regression model was potentially inappropriate. We therefore conducted further examinations using another regression model.

Factors associated with depressive state
----------------------------------------

Mean +2 SDs for the Japanese standard BDI-II score is 21.5,[@b8] approximately equal to the cut-off level indicative of moderate or worse depression (BDI-II \>20) in the original English version.[@b5; @b6; @b7] We thus defined BDI-II \>21.5 as indicating depressive state, with a frequency of 13.6% (39 of 287) among patients with MG in this study. In the present subjects, as no patients showed BDI-II=21, the total of 39 patients with depressive state using our definition (BDI-II \>21.5) was identical to the result we would have achieved if a cut-off of BDI-II \>20 had been used. Backgrounds of patients with or without depressive state and comparison between the two groups were shown in [table 2](#tbl2){ref-type="table"}.

###### 

Comparison between patients with and without depressive state

  Clinical factors               Patients with depressive state (n=39)   Patients without depressive state (n=248)
  ------------------------------ --------------------------------------- -------------------------------------------
  Age (years)                    52.3±18.0                               58.2±16.9
  Female                         n=28                                    n=165
  Time since onset (years)       6.1±6.2\*                               9.3±8.4
  Age at onset (years)           46.1±18.7                               48.3±18.6
  Thymectomy                     n=12                                    n=129
  Thymoma                        n=7                                     n=56
  QMG                            9.9±6.6\*\*                             6.6±4.7
  Ocular QMG                     2.5±2.2\*                               1.6±1.7
  Bulbar QMG                     0.5±1.2                                 0.3±0.7
  MG composite                   10.4±7.8\*\*\*                          5.7±5.5
  MG-ADL                         5.3±4.0\*\*                             3.1±2.9
  MGFA classification (worst)    I/II/III/IV/V: 7/13/14/2/4              I/II/III/IV/V: 61/112/46/10/18
  Current dose of PSL (mg/day)   8.1±7.0\*\*\*                           4.1±5.6
  Maximum dose of PSL (mg/day)   20.4±21.6                               20.5±20.6
  Calcineurin inhibitors         n=19                                    n=96
  Crisis                         n=4                                     n=18
  AChR-Ab positivity             n=24                                    n=208
  Kv 1.4-Ab positivity           n=6                                     n=31
  Titin-Ab positivity            n=8                                     n=45
  CSR                            n=0                                     n=21
  PR                             n=1                                     n=21
  MM                             n=4                                     n=91
  I                              n=11                                    n=80
  U                              n=13                                    n=41
  W                              n=2                                     n=2

\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 (Mann--Whitney U test) compared to patients without depressive state; no significant difference in categorical variables between patients with and without depressive state (χ^2^ test).

AChR-Ab, antibodies against acetylcholine receptor; CSR, complete stable remission; I, improved; Kv1.4, voltage-gated potassium channel 1.4; MG-ADL, MG activities of daily living scale; MG composite, MG composite scale; MGFA, Myasthenia Gravis Foundation of America; MM, minimal manifestations; MuSK, muscle-specific tyrosine kinase; PR, pharmacologic remission; PSL, prednisolone; QMG, MGFA quantitative MG score; U, unchanged; W, worse.

Clinical factors associated with depressive state were examined by logistic regression analysis. Factors displaying a p value of \<0.05 in univariate logistic regression analysis were time since onset, QMG, ocular QMG, MG composite, MG-ADL, current dose of PSL, use of calcineurin inhibitors and U and Worse (W) MGFA postintervention status ([table 3](#tbl3){ref-type="table"}). These factors were entered into multivariate logistic regression analysis for determination of independent background factors associated with depressive state. Multivariate logistic regression analysis revealed current dose of PSL (OR 1.09, 95% CI 1.02 to 1.17; p=0.01), U of MGFA postintervention status (OR 3.55, 95% CI 1.18 to 10.71; p=0.02), time since onset (OR 0.93, 95% CI 0.87 to 0.99; p=0.03) and MG composite (OR 1.16, 95% CI 1.00 to 1.34; p=0.046) as independent background factors associated with depressive state in MG.

###### 

Clinical factors associated with depressive state (univariate logistic regression)

  Clinical factors                   OR (95% CI)            p Value
  ---------------------------------- ---------------------- -----------------------------------------------
  Age (years)                        0.98 (0.96 to 1.00)    0.060
  Female                             1.41 (0.63 to 3.14)    0.41
  Time since onset (years)           0.94 (0.89 to 1.00)    0.041[\*](#table-fn3){ref-type="table-fn"}
  Age at onset (years)               0.99 (0.97 to 1.01)    0.51
  Thymectomy                         0.39 (0.18 to 1.24)    0.27
  Thymoma                            0.91 (0.38 to 2.20)    0.84
  QMG                                1.12 (1.05 to 1.19)    0.0007[\*](#table-fn3){ref-type="table-fn"}
  Ocular QMG                         1.26 (1.05 to 1.52)    \<0.012[\*](#table-fn3){ref-type="table-fn"}
  Bulbar QMG                         1.36 (0.94 to 1.98)    0.10
  MG composite                       1.14 (1.08 to 1.20)    \<0.0001[\*](#table-fn3){ref-type="table-fn"}
  MG-ADL                             1.21 (1.09 to 1.35)    0.0003[\*](#table-fn3){ref-type="table-fn"}
  MGFA classification (worst)        1.19 (0.88 to 1.62)    0.26
  Current dose of PSL (mg/day)       1.09 (1.04 to 1.15)    0.0006[\*](#table-fn3){ref-type="table-fn"}
  Maximum dose of PSL (mg/day)       1.00 (0.98 to 1.02)    0.97
  Calcineurin inhibitors             2.07 (1.01 to 4.27)    0.048[\*](#table-fn3){ref-type="table-fn"}
  Crisis                             0.93 (0.26 to 3.29)    0.91
  AChR-Ab positivity                 1.00 (1.00 to 1.01)    0.28
  Kv 1.4-Ab positivity               1.92 (0.70 to 5.26)    0.20
  Titin-Ab positivity                1.71 (0.93 to 3.14)    0.10
  CSR (no case with BDI-II \>21.5)   Not determined         Not determined
  PR                                 0.30 (0.04 to 2.28)    0.24
  MM                                 0.54 (0.24 to 1.24)    0.15
  I                                  1.24 (0.59 to 2.60)    0.57
  U                                  3.14 (1.46 to 6.77)    0.004[\*](#table-fn3){ref-type="table-fn"}
  W                                  5.93 (1.27 to 27.73)   0.023[\*](#table-fn3){ref-type="table-fn"}

Variables entered into multivariate logistic regression analysis (see the Results section in the text).

AChR-Ab, antibodies against acetylcholine receptor; CSR, complete stable remission; I, improved; Kv1.4, voltage-gated potassium channel 1.4; MG-ADL, MG activities of daily living scale; MG composite, MG composite scale; MGFA, Myasthenia Gravis Foundation of America; MM, minimal manifestations; MuSK, muscle-specific tyrosine kinase; PR, pharmacologic remission; PSL, prednisolone; QMG, MGFA quantitative MG score; U, unchanged; W, worse.

Discussion
==========

The present study examined associations between detailed parameters of MG and self-reported depressive symptoms and revealed current dose of oral PSL as the most significant background for depressive state in MG. In fact, long-term use of corticosteroids has been suggested to affect the brain and result in the development of depressive conditions.[@b13; @b14; @b15] Complications of long-term corticosteroid use emerge at around 10 mg/day of prednisone or PSL.[@b13; @b14; @b15] Consistently, mean dose of oral PSL in patients with MG in depressive state was 8.1 mg/day, significantly higher than that in patients without depressive state (4.1 mg/day; p\<0.001 using Mann--Whitney U test). Although oral corticosteroids represent the first-line and most common agents for immunosuppressive treatment of MG,[@b16] the present results indicate a possible need for attention to dose and associated depressive side effects. The constant need for medication itself might also cause psychological stress, but use of calcineurin inhibitors (ie, cyclosporine microemulsion and tacrolimus) was not associated with depressive state. In Japan, oral cyclosporine microemulsion (2.0--5.0 mg/kg/day) was divided into two doses taken at intervals of 12 h, and oral tacrolimus (3.0--4.0 mg/day) was given once a day. There may be some differences of prescription pattern among Japan and other countries.

BDI-II score for patients with MG did not differ substantially from and overlapped with that of the Japanese standard. The frequency of individuals with depressive state (BDI-II \>21.5) was 13.6% in this study, lower than that reported by Fisher *et al*.[@b7] They reported that moderate or worse depression (BDI-II \>20 in the original English version) was observed in 33% (15/45) of patients with MG.[@b7] The frequency of depressive symptoms in patients with MG has been inconsistent in previous reports.[@b1; @b2; @b3] Anxiety or depressive disorders have been reported as more frequent among patients with MG than in the general population.[@b4] [@b17] Conversely, several authors have found no increased frequency of depression among patients with MG compared to the general population.[@b18; @b19; @b20] Regarding such discrepancies, given that the present study showed depressive symptoms to be positively correlated with both severity of MG and corticosteroid dose, frequency of depressive patients with MG may alter depending on such background factors in subjects.

The present analysis revealed that unchanged status despite treatment and early disease stage are also significant background factors for depressive state, along with disease severity. These findings suggest that achieving early improvement of disease by adequate somatic therapy against MG may be important to avoid a depressive state.[@b3] [@b18] Psychiatric symptoms have also been noted to emerge temporarily in exacerbated patients with MG, reversing if adequate somatic therapy is given.[@b3] [@b4]

Lack of formal evaluation of psychopathological characteristics by psychiatrists may represent a limitation to the present study. Patients with MG have been suggested to exhibit symptoms characteristically similar to the vegetative signs of affective disorders, which may interfere with correct assessment of mood if using only self-rating depression scales.[@b19] [@b20]

In conclusion, dose of oral corticosteroids appears to represent the major factor associated with depressive state in patients with MG. Unchanged status despite treatment and early disease stage are also significant background factors for depressive state, along with disease severity. Achieving early improvement of disease by adequate MG therapy without long-term use of higher dose oral corticosteroids may be important to avoiding depressive state in patients with MG.
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